Persistent Asset Partners Ltd Purchases New Shares in Palisade Bio, Inc. $PALI

Persistent Asset Partners Ltd purchased a new stake in shares of Palisade Bio, Inc. (NASDAQ:PALI) during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 416,035 shares of the company’s stock, valued at approximately $978,000.

Other hedge funds also recently made changes to their positions in the company. Franklin Resources Inc. purchased a new stake in Palisade Bio in the fourth quarter worth about $11,968,000. Renaissance Technologies LLC purchased a new stake in Palisade Bio in the fourth quarter worth about $5,599,000. Vivo Capital LLC purchased a new stake in Palisade Bio in the fourth quarter worth about $5,390,000. Geode Capital Management LLC grew its holdings in Palisade Bio by 5,780.7% in the fourth quarter. Geode Capital Management LLC now owns 1,565,452 shares of the company’s stock worth $3,681,000 after purchasing an additional 1,538,832 shares during the period. Finally, Exome Asset Management LLC purchased a new stake in Palisade Bio in the fourth quarter worth about $1,782,000. 11.79% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the stock. Weiss Ratings cut shares of Palisade Bio from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, June 9th. Stifel Nicolaus assumed coverage on shares of Palisade Bio in a report on Wednesday, February 25th. They issued a “buy” rating and a $5.00 price objective on the stock. Wall Street Zen upgraded shares of Palisade Bio from a “sell” rating to a “hold” rating in a report on Saturday, February 28th. Wolfe Research initiated coverage on Palisade Bio in a report on Thursday, April 9th. They set an “outperform” rating and a $7.00 price target for the company. Finally, HC Wainwright initiated coverage on Palisade Bio in a report on Thursday, March 26th. They set a “buy” rating and a $7.00 price target for the company. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $10.20.

Palisade Bio Stock Up 5.3%

Shares of NASDAQ PALI opened at $1.78 on Wednesday. Palisade Bio, Inc. has a twelve month low of $0.53 and a twelve month high of $2.86. The firm has a market cap of $308.97 million, a P/E ratio of -1.76 and a beta of 1.52. The company has a 50 day moving average of $1.98 and a 200 day moving average of $1.91.

Palisade Bio (NASDAQ:PALI) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.01). As a group, equities analysts expect that Palisade Bio, Inc. will post -0.21 earnings per share for the current fiscal year.

About Palisade Bio

Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.